Vaccines: All things considered
1 Modeling and Simulation: Tool for Optimized Drug Development Martin Roessner Biostatistics sanofi aventis Bridgewater, NJ.
The Essentials of “Dosing Interval” Larry Goldkind M.D. Deputy Division Director, Division of Anti-Inflammatory, Analgesics, and Ophthalmic Drug Products.
Optimizing Medication Treatment in Children, Adolescents and Adults with ADHD
Treating Cancer
A Bayesian Industry Approach to Phase 1 Combination Trials in Oncology
2014-10-22 EUGM | ROYCHAUDHURI | Phase I Combination Trials
Mine...
Phase I dose escalation studies in Oncology: a call for on-study safety and flexibility Bill Mietlowski, Biometrics and Data Management, Novartis Oncology.
Adapting for Success: The Genesis of Adaptive Designs Andy Grieve SVP Clinical Trials Methodology, Innovation Centre, Aptiv Solutions. 1.
New Directions for Treatment in ALS Robert G. Miller, M.D. Forbes Norris MDA/ALS Research Center California Pacific Medical Center San Francisco, CA May.
Testing treatment combinations versus the corresponding monotherapies in clinical trials Ekkekhard Glimm, Novartis Pharma AG 8th Tartu Conference on Multivariate.
